Key result
In patients with atrial fibrillation receiving aspirin, biomarkers including F1.2, BTG, fibrinogen, and factor V Leiden (RR 0.5; 95% CI 0.1-3.8) were not independent predictors of stroke.
Why the study?
Do markers of thrombin generation and platelet activation predict thromboembolism in patients with atrial fibrillation?
Cohort (n=1,531)
Do markers of thrombin generation and platelet activation predict thromboembolism in patients with atrial fibrillation?
Effect estimate: RR 0.5 (95% CI 0.1 to 3.8)
Markers of thrombin generation and platelet activation (F1.2, BTG, fibrinogen, factor V Leiden) are not clinically useful independent predictors of stroke in patients with atrial fibrillation receiving aspirin.
No takes yet. Share an insight, caveat, or question.
Biomarkers lack independent predictive value for stroke in aspirin-treated AF; leaves open utility in other regimens or risk models.
Feinberg et al. (1999) conducted a cohort in Atrial Fibrillation (n=1,531). Biomarkers (F1.2, BTG, fibrinogen, factor V Leiden) was evaluated on Thromboembolism (ischemic stroke and systemic embolism) (RR 0.5, 95% CI 0.1 to 3.8). In patients with atrial fibrillation receiving aspirin, biomarkers including F1.2, BTG, fibrinogen, and factor V Leiden (RR 0.5; 95% CI 0.1-3.8) were not independent predictors of stroke.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: